Compare Berkshire Hathaway Inc Class B (BRK.B) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Berkshire Hathaway Inc Class B vs Recursion Pharmaceuticals Inc — how do they compare? Berkshire Hathaway Inc Class B trades at $490.5, while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B). The key difference: Berkshire Hathaway Inc Class B is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| BRK.B | RXRX | |
|---|---|---|
Sector | Financials | Health |
52-Week High | $513.70 | $6.79 |
52-Week Low | $459.10 | $2.84 |
Market Cap | — | $1.78B |
Enterprise Value | — | $1.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BRK.B trades at $490.00, down 1.37% on the day. The technical picture shows a bullish moving average signal but neutral oscillators, with immediate support at $489 and resistance at $495. Analyst consensus is bullish with 57% buy ratings and no sell recommendations. The stock's valuation metrics are not provided in the current dataset.
The outlook is cautiously positive based on analyst sentiment and technical positioning near support. Key risks include market volatility and the company's exposure to broad economic cycles. The absence of current fundamental data necessitates direct review of Berkshire Hathaway's latest SEC filings for a complete investment picture.
RXRX trades at $3.30, down 7.3% today, with bearish technical signals from moving averages and oscillators. The clinical-stage biotech shows severe financial strain with a -851.51% net income margin and negative cash flow from operations of -$372M in 2025, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights AI-driven drug discovery potential but questions commercial viability.
Despite analyst consensus price target of $7.83 suggesting 137% upside, high cash burn and unproven business model pose substantial risk. Investment appeal hinges on successful drug development milestones, but current fundamentals indicate speculative positioning suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Berkshire Hathaway Inc Class B
Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.
Read more on BRK.B →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
